10:44 AM EST - BELLUS Health Inc. : Announced the appointment of a world-class clinical advisory board. The CAB will provide strategic guidance and support to the development of BLU-5937, BELLUS Health's lead drug candidate for chronic cough, as the Company prepares for a clinical Phase 2 study. BLU-5937 is currently in a clinical Phase 1 study and results are expected in the fourth quarter of 2018. The first meeting of the CAB was held on September 24 in London, England. BELLUS Health Inc.
shares T.BLU are trading up $0.04 at $1.07.
